5J3.F SCIBASE HOLDING AB
- Market cap
- EUR 168K
- P/E
- -
- P/B
- 6.18x
- ROE
- -353.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5J3.F undervalued?
Graham numberThe Graham number of SCIBASE HOLDING AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCIBASE HOLDING AB fundamental analysis
No fundamental analysis for SCIBASE HOLDING AB yet.
SCIBASE HOLDING AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCIBASE HOLDING AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment. It has a collaboration w…
Full company profileSCIBASE HOLDING AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SCIBASE HOLDING AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 11.7M | 17.9M | 23.2M | 29.7M | 40.5M | 59.2M |
| Gross Profit | 6.58M | 11.2M | 16.0M | 21.1M | 27.1M | 30.2M |
| Operating Income | -42.4M | -46.4M | -53.9M | -67.0M | -85.2M | -107M |
| EBITDA | - | -39.3M | -51.8M | -62.1M | -82.9M | -106M |
| Net Income | -41.8M | -43.2M | -55.6M | -65.6M | -87.1M | -107M |
| EPS | -0.49 | -0.51 | -0.39 | -0.25 | -0.18 | -9.93 |
| Balance Sheet | ||||||
| Total Assets | 85.5M | 49.9M | 64.3M | 61.7M | 52.2M | 73.0M |
| Total Liabilities | 14.7M | 24.6M | 21.3M | 25.1M | 45.5M | 42.8M |
| Shareholders' Equity | 70.8M | 25.2M | 43.1M | 36.7M | 6.66M | 30.2M |
| Cash & Short-term Investments | 65.6M | 18.8M | 34.1M | 11.2M | 22.6M | 37.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -39.5M | -44.5M | -52.0M | -57.4M | -84.6M | -119M |
| Capital Expenditure | 617K | 381K | 383K | 428K | 228K | 828K |
| Free Cash Flow | -40.1M | -44.8M | -52.4M | -57.8M | -84.8M | -120M |
| Ratios | ||||||
| ROE | -59.0% | -171.1% | -129.1% | -178.9% | -1,308.0% | -353.3% |
| ROA | -48.9% | -86.6% | -86.4% | -106.2% | -166.9% | -146.3% |
| Net Profit Margin | -356.3% | -241.3% | -239.1% | -220.8% | -215.2% | -180.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SCIBASE HOLDING AB dividends
SCIBASE HOLDING AB has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on Jun 4, 2026.
Who owns SCIBASE HOLDING AB
- Insiders 22.83%
- Institutions 4.94%
- Public & others 72.24%
- Shares outstanding 10.2M
- Free float 746M
SCIBASE HOLDING AB company profile
- Company name
- SCIBASE HOLDING AB
- Ticker
- 5J3.F
- ISIN
- SE0007045414
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 46
- Fiscal year end
- December
- Address
- LandsvAegen 39, Sundbyberg, Sweden, 172 63
- Phone
- 46 8 41 06 20 00
- Website
- scibase.com
About SCIBASE HOLDING AB
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment. It has a collaboration with Mayo Clinic on pigmented lesion digital workflows with AI-driven Nevisense.SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
SCIBASE HOLDING AB management
8- Ms. Pia RenaudinChief Executive Officer · born 1967
- Dr. Stig Ollmar Ph.D.Founder & Chief Scientific Officer · born 1946
- Mr. Michael ColérusChief Financial Officer · born 1962
- Ms. Linn OlsenChief Operating Officer · born 1977
- Ms. Angelica KorsfeldtChief Technology Officer · born 1989
- Jennifer Sparen BengtssonHead of Sales & Marketing · born 1969
- Mr. Per SvedenhagHead of Business Development · born 1958
- Ms. Leda BeatyPresident of SciBase Inc · born 1971